Logo image of AMLX

AMYLYX PHARMACEUTICALS INC (AMLX) Stock Fundamental Analysis

USA - NASDAQ:AMLX - US03237H1014 - Common Stock

13.48 USD
+0.17 (+1.28%)
Last: 9/23/2025, 8:00:00 PM
13.49 USD
+0.01 (+0.07%)
Pre-Market: 9/24/2025, 7:17:13 AM
Fundamental Rating

3

Taking everything into account, AMLX scores 3 out of 10 in our fundamental rating. AMLX was compared to 196 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for AMLX as it has an excellent financial health rating, but there are worries on the profitability. AMLX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AMLX has reported negative net income.
AMLX had a negative operating cash flow in the past year.
In the past 5 years AMLX reported 4 times negative net income.
AMLX had negative operating cash flow in 4 of the past 5 years.
AMLX Yearly Net Income VS EBIT VS OCF VS FCFAMLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

The Return On Assets of AMLX (-96.40%) is worse than 74.49% of its industry peers.
With a Return On Equity value of -111.75%, AMLX is not doing good in the industry: 60.71% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -96.4%
ROE -111.75%
ROIC N/A
ROA(3y)-65.66%
ROA(5y)-116%
ROE(3y)-76.67%
ROE(5y)-224.39%
ROIC(3y)N/A
ROIC(5y)N/A
AMLX Yearly ROA, ROE, ROICAMLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AMLX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AMLX Yearly Profit, Operating, Gross MarginsAMLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

AMLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AMLX has been increased compared to 1 year ago.
The number of shares outstanding for AMLX has been increased compared to 5 years ago.
AMLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AMLX Yearly Shares OutstandingAMLX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
AMLX Yearly Total Debt VS Total AssetsAMLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

AMLX has an Altman-Z score of 25.66. This indicates that AMLX is financially healthy and has little risk of bankruptcy at the moment.
AMLX has a Altman-Z score of 25.66. This is amongst the best in the industry. AMLX outperforms 93.88% of its industry peers.
AMLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 25.66
ROIC/WACCN/A
WACC9.82%
AMLX Yearly LT Debt VS Equity VS FCFAMLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 8.72 indicates that AMLX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.72, AMLX is in the better half of the industry, outperforming 79.08% of the companies in the same industry.
A Quick Ratio of 8.72 indicates that AMLX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 8.72, AMLX belongs to the best of the industry, outperforming 80.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.72
Quick Ratio 8.72
AMLX Yearly Current Assets VS Current LiabilitesAMLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for AMLX have decreased strongly by -420.83% in the last year.
AMLX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -99.86%.
The Revenue has been growing by 127.75% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-420.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.99%
Revenue 1Y (TTM)-99.86%
Revenue growth 3Y574.28%
Revenue growth 5Y127.75%
Sales Q2Q%100%

3.2 Future

Based on estimates for the next years, AMLX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.78% on average per year.
Based on estimates for the next years, AMLX will show a quite strong growth in Revenue. The Revenue will grow by 18.41% on average per year.
EPS Next Y23.73%
EPS Next 2Y15.23%
EPS Next 3Y10.77%
EPS Next 5Y13.78%
Revenue Next Year-100%
Revenue Next 2Y-96.76%
Revenue Next 3Y-35.34%
Revenue Next 5Y18.41%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AMLX Yearly Revenue VS EstimatesAMLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
AMLX Yearly EPS VS EstimatesAMLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AMLX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AMLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMLX Price Earnings VS Forward Price EarningsAMLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMLX Per share dataAMLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.23%
EPS Next 3Y10.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AMLX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMYLYX PHARMACEUTICALS INC

NASDAQ:AMLX (9/23/2025, 8:00:00 PM)

Premarket: 13.49 +0.01 (+0.07%)

13.48

+0.17 (+1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners75.81%
Inst Owner Change10.56%
Ins Owners9.33%
Ins Owner Change-0.49%
Market Cap1.44B
Analysts86.25
Price Target12.88 (-4.45%)
Short Float %9.35%
Short Ratio5.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6%
Min EPS beat(2)-1.31%
Max EPS beat(2)13.31%
EPS beat(4)1
Avg EPS beat(4)-9.86%
Min EPS beat(4)-47.75%
Max EPS beat(4)13.31%
EPS beat(8)2
Avg EPS beat(8)-250.07%
EPS beat(12)6
Avg EPS beat(12)-138.26%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.6%
PT rev (3m)16.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.26%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3456.19
P/FCF N/A
P/OCF N/A
P/B 8.56
P/tB 8.56
EV/EBITDA N/A
EPS(TTM)-2.5
EYN/A
EPS(NY)-1.66
Fwd EYN/A
FCF(TTM)-1.89
FCFYN/A
OCF(TTM)-1.55
OCFYN/A
SpS0
BVpS1.57
TBVpS1.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -96.4%
ROE -111.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.66%
ROA(5y)-116%
ROE(3y)-76.67%
ROE(5y)-224.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5343.95%
Cap/Sales 8709.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.72
Quick Ratio 8.72
Altman-Z 25.66
F-Score3
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)1551.62%
Cap/Depr(5y)4086.74%
Cap/Sales(3y)17.77%
Cap/Sales(5y)40.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-420.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.99%
EPS Next Y23.73%
EPS Next 2Y15.23%
EPS Next 3Y10.77%
EPS Next 5Y13.78%
Revenue 1Y (TTM)-99.86%
Revenue growth 3Y574.28%
Revenue growth 5Y127.75%
Sales Q2Q%100%
Revenue Next Year-100%
Revenue Next 2Y-96.76%
Revenue Next 3Y-35.34%
Revenue Next 5Y18.41%
EBIT growth 1Y-157.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.82%
EBIT Next 3Y12.04%
EBIT Next 5YN/A
FCF growth 1Y-122.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-85.63%
OCF growth 3YN/A
OCF growth 5YN/A